Ascendis Pharma Closes $124 Million Initial Public Offering

Palo Alto – February 13, 2015 – Cooley advised the underwriters on Ascendis Pharma A/S's $124.2 million initial public offering. Ascendis Pharma is a clinical-stage biopharmaceutical company applying its TransCon technology to develop a pipeline of therapies to address significant unmet medical needs. The company now trades on The Nasdaq Global Market under the symbol "ASND."

Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Partners LLC acted as the joint book-running managers and Wells Fargo Securities, LLC acted as co-manager for the offering.

The Cooley corporate securities team advising the underwriters was comprised of partners Div Gupta, Drew Williamson and Charlie Kim, as well as associates Jonie Ing Kondracki, Carolyn Mo, Kristin VanderPas and Jenny Baer Tuohy.

Critical support for the offering was provided by partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (health care and life sciences regulatory); partner Bill Christiansen (intellectual property); partner Lila Hope and associate Jennifer Raab (life sciences partnering); special counsel Laura McDaniels (compensation and benefits); and partner Susan Cooper Philpot (tax).

About Cooley LLP

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.